Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

Fapon Biopharma today announced that Dr. Kaiqing Zhang, Ph.D., Associate Director of Business/Corporate Development, will ...

The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.

UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate.

Astellas Pharma Inc. and Vir Biotechnology Inc. have signed a global co-development pact to advance VIR-5500, Vir’s PRO-XTEN dual-masked CD3 T-cell engager targeting prostate-specific membrane antigen ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Astellas Pharma Inc. and Vir Biotechnology Inc. have signed a global co-development pact to advance VIR-5500, Vir’s PRO-XTEN dual-masked CD3 T-cell engager targeting prostate-specific membrane antigen ...

CEO Martin Lehr outlined the company’s strategy and upcoming clinical milestones at the 46th Annual TD Cowen Healthcare Conference, positioning the biotechnology company as a developer of T-cell ...

Genetically engineered immune cells known as CAR-T cells might be able to slow the progress of the neurodegenerative condition amyotrophic lateral sclerosis (ALS) by killing off rogue immune cells in ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite prostaglandin E2 can block T cells—the killer cells of the immune system—in the ...

BioAtla has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor. There can be no assurance that this process will result in any such transaction. BioAtla does not intend ...